Wenxiu Yao
Overview
Explore the profile of Wenxiu Yao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, et al.
Lancet Respir Med
. 2025 Feb;
PMID: 39914443
Background: This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC)....
2.
Zhao Y, Xiong S, Ren Q, Wang J, Li M, Yang L, et al.
Lancet Oncol
. 2024 Dec;
26(1):136-146.
PMID: 39653054
Background: Accurate detection of driver gene mutations is crucial for treatment planning and predicting prognosis for patients with lung cancer. Conventional genomic testing requires high-quality tissue samples and is time-consuming...
3.
Shen Q, Tang C, Xu X, Liu G, Shao S, Yao W, et al.
J Chromatogr A
. 2024 Jul;
1730:465159.
PMID: 39025022
Based on the adhesion of polyethyleneimine (PEI), a novel PEI/zein co-modified core-shell stationary phase (PEI/Zein@SiO) was prepared by doping zein to form a composite modification layer. The stationary phase achieved...
4.
Cheng Y, Wu L, Huang D, Wang Q, Fan Y, Zhang X, et al.
Lung Cancer
. 2024 Jan;
188:107455.
PMID: 38224653
Introduction: Trilaciclib is a transient cyclin-dependent kinase 4/6 inhibitor that decreases the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). TRACES study was designed to assess the...
5.
Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, et al.
Thorac Cancer
. 2024 Jan;
15(5):419-426.
PMID: 38219795
Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs);...
6.
Drilon A, Camidge D, Lin J, Kim S, Solomon B, Dziadziuszko R, et al.
N Engl J Med
. 2024 Jan;
390(2):118-131.
PMID: 38197815
Background: The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of fusion-positive non-small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial...
7.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, et al.
Nat Cancer
. 2024 Jan;
5(1):209.
PMID: 38182915
No abstract available.
8.
Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, et al.
Br J Cancer
. 2023 Dec;
130(3):450-456.
PMID: 38110665
Background: Cadonilimab is a bispecific antibody that simultaneously targets programmed cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to assess the safety and efficacy of cadonilimab plus...
9.
Huang D, Lin G, Chu Q, Hu Y, Wang J, Wang Z, et al.
Thorac Cancer
. 2023 Nov;
14(34):3421-3429.
PMID: 37963454
Immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 blockade) have revolutionized the treatment landscape in non-small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical...
10.
Tian L, Yao W, Wu Y, Wang Q, Shen H, Zheng Y, et al.
Opt Lett
. 2023 Aug;
48(15):3909-3912.
PMID: 37527080
Reversed nonlinear dynamics is predicted to be capable of enhancing the quantum sensing in unprecedented ways. Here, we report the experimental demonstration of a loss-tolerant (external loss) and quantum-enhanced interferometer....